Stock DNA
Computers - Software & Consulting
USD 1,431 Million (Micro Cap)
38.00
NA
0.00%
0.33
7.01%
2.23
Total Returns (Price + Dividend) 
GoodRx Holdings, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
Is GoodRx Holdings, Inc. overvalued or undervalued?
As of 21 November 2025, the valuation grade for GoodRx Holdings, Inc. has moved from attractive to very attractive. Despite this positive change, the company appears to be overvalued based on its current P/E ratio of 38, which is significantly higher than the peer average of approximately 31.76 for similar companies. Additionally, the EV to EBITDA ratio stands at 9.64, indicating a premium compared to some peers, while the Price to Book Value is 2.23, suggesting that the market is pricing the stock at a higher value relative to its book value. When compared to its peers, GoodRx's valuation ratios indicate a disparity, particularly against PropertyGuru Group Ltd. and ZipRecruiter, Inc., which have P/E ratios of -132.05 and -12.45, respectively. This context highlights that GoodRx's valuation may not be justified given its performance metrics, such as a ROE of 5.92% and a ROCE of 11.40%. Furthermore, the com...
Read More
GoodRx Holdings Hits 52-Week Low at $3.21 Amidst Significant Decline
GoodRx Holdings, Inc. has hit a new 52-week low, reflecting a significant decline over the past year. Despite this downturn, the company reported positive financial metrics, including strong operating cash flow and net profit. Institutional investors maintain a substantial stake, indicating confidence in its fundamentals.
Read More
GoodRx Holdings Hits 52-Week Low at $3.25 Amid Significant Decline
GoodRx Holdings, Inc. has reached a new 52-week low, reflecting a significant decline over the past year. Despite this downturn, the company reported strong financial metrics, including high operating cash flow and net profit. GoodRx also has a substantial market capitalization and high institutional ownership, indicating investor confidence.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 36 Schemes (17.85%)
Held by 95 Foreign Institutions (8.88%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 0.05% vs 2.22% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 15.32% vs 65.67% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 5.60% vs -2.13% in Dec 2023
YoY Growth in year ended Dec 2024 is 284.27% vs 72.87% in Dec 2023






